BRPI0407793A - tratamento de osteólise excessiva com compostos de indolinona - Google Patents
tratamento de osteólise excessiva com compostos de indolinonaInfo
- Publication number
- BRPI0407793A BRPI0407793A BRPI0407793-8A BRPI0407793A BRPI0407793A BR PI0407793 A BRPI0407793 A BR PI0407793A BR PI0407793 A BRPI0407793 A BR PI0407793A BR PI0407793 A BRPI0407793 A BR PI0407793A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- compounds
- excessive osteolysis
- indolinone compounds
- osteolysis
- Prior art date
Links
- 208000003076 Osteolysis Diseases 0.000 title abstract 3
- 208000029791 lytic metastatic bone lesion Diseases 0.000 title abstract 3
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- -1 INDOLINONE COMPOUNDS Chemical class 0.000 abstract 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000002997 osteoclast Anatomy 0.000 abstract 1
- 230000026731 phosphorylation Effects 0.000 abstract 1
- 238000006366 phosphorylation reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44886103P | 2003-02-24 | 2003-02-24 | |
| US10/780,917 US20040209937A1 (en) | 2003-02-24 | 2004-02-19 | Treatment of excessive osteolysis with indolinone compounds |
| PCT/US2004/005283 WO2004075775A2 (en) | 2003-02-24 | 2004-02-23 | Treatment of excessive osteolyisis with indolinone compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0407793A true BRPI0407793A (pt) | 2006-02-14 |
Family
ID=32930497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0407793-8A BRPI0407793A (pt) | 2003-02-24 | 2004-02-23 | tratamento de osteólise excessiva com compostos de indolinona |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20040209937A1 (enExample) |
| EP (1) | EP1599207A2 (enExample) |
| JP (1) | JP2006518756A (enExample) |
| KR (1) | KR20050113612A (enExample) |
| AU (1) | AU2004216188A1 (enExample) |
| BR (1) | BRPI0407793A (enExample) |
| CA (1) | CA2516786A1 (enExample) |
| MX (1) | MXPA05008961A (enExample) |
| NZ (1) | NZ541825A (enExample) |
| PL (1) | PL378762A1 (enExample) |
| WO (1) | WO2004075775A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006245421A1 (en) * | 2005-05-12 | 2006-11-16 | Pfizer Inc. | Anticancer combination therapy using sunitinib malate |
| WO2007034272A1 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | Solid salt forms of a pyrrole substituted 2-indolinone |
| EP1977238B1 (en) * | 2005-12-22 | 2016-09-28 | Novartis AG | Soluble human m-csf receptor and uses thereof |
| CN101367801B (zh) | 2007-08-15 | 2011-01-12 | 上海恒瑞医药有限公司 | 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用 |
| CN102137842A (zh) * | 2008-07-02 | 2011-07-27 | 基因里克斯(英国)有限公司 | 3-吡咯取代的2-吲哚酮衍生物的制备 |
| CA2730079A1 (en) * | 2008-07-10 | 2010-01-14 | Generics [Uk] Limited | Processes for the preparation of crystalline forms of sunitinib malate |
| WO2010011834A2 (en) * | 2008-07-24 | 2010-01-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib and salts thereof and their polymorphs |
| CN102239163A (zh) * | 2008-07-24 | 2011-11-09 | 特瓦制药工业有限公司 | 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法 |
| EP2181991A1 (en) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
| EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| US10898211B2 (en) | 2015-01-14 | 2021-01-26 | Crossroads Extremity Systems, Llc | Opening and closing wedge osteotomy guide and method |
| US10292713B2 (en) | 2015-01-28 | 2019-05-21 | First Ray, LLC | Freeform tri-planar osteotomy guide and method |
| US10376268B2 (en) | 2015-02-19 | 2019-08-13 | First Ray, LLC | Indexed tri-planar osteotomy guide and method |
| EP3470394B1 (en) * | 2016-06-09 | 2022-01-26 | Yuki Gosei Kogyo Co., Ltd. | Method for preparing 4-(piperidin-4-yl)morpholine |
| CN114513994B (zh) | 2019-07-26 | 2025-08-01 | 汇聚义肢系统有限责任公司 | 骨复位引导系统和方法 |
| US11779359B2 (en) | 2020-02-19 | 2023-10-10 | Crossroads Extremity Systems, Llc | Systems and methods for Lapidus repair of bunions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1255752E (pt) * | 2000-02-15 | 2007-10-17 | Pharmacia & Upjohn Co Llc | Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| EP1434774A1 (en) * | 2001-10-10 | 2004-07-07 | Sugen, Inc. | 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors |
| US20040018528A1 (en) * | 2002-05-17 | 2004-01-29 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
-
2004
- 2004-02-19 US US10/780,917 patent/US20040209937A1/en not_active Abandoned
- 2004-02-23 AU AU2004216188A patent/AU2004216188A1/en not_active Abandoned
- 2004-02-23 JP JP2006503797A patent/JP2006518756A/ja not_active Withdrawn
- 2004-02-23 BR BRPI0407793-8A patent/BRPI0407793A/pt not_active IP Right Cessation
- 2004-02-23 MX MXPA05008961A patent/MXPA05008961A/es unknown
- 2004-02-23 EP EP04713729A patent/EP1599207A2/en not_active Withdrawn
- 2004-02-23 PL PL378762A patent/PL378762A1/pl not_active Application Discontinuation
- 2004-02-23 CA CA002516786A patent/CA2516786A1/en not_active Abandoned
- 2004-02-23 KR KR1020057015602A patent/KR20050113612A/ko not_active Withdrawn
- 2004-02-23 NZ NZ541825A patent/NZ541825A/en unknown
- 2004-02-23 WO PCT/US2004/005283 patent/WO2004075775A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| PL378762A1 (pl) | 2006-05-15 |
| AU2004216188A1 (en) | 2004-09-10 |
| US20040209937A1 (en) | 2004-10-21 |
| NZ541825A (en) | 2008-11-28 |
| MXPA05008961A (es) | 2005-11-04 |
| WO2004075775A2 (en) | 2004-09-10 |
| KR20050113612A (ko) | 2005-12-02 |
| JP2006518756A (ja) | 2006-08-17 |
| EP1599207A2 (en) | 2005-11-30 |
| WO2004075775A3 (en) | 2005-04-14 |
| CA2516786A1 (en) | 2004-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0407793A (pt) | tratamento de osteólise excessiva com compostos de indolinona | |
| GT200500242A (es) | Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
| BR112013000868A2 (pt) | derivados de pirazol [1,5a] e tieno [3,2b] pirimidina como modulares de irak4 | |
| JO2848B1 (en) | Organic compounds | |
| BRPI0710521A2 (pt) | quinazolinas para inibição de pdk1 | |
| GT200500103A (es) | 4-fenilamino-quinazolin-6-il-amidas | |
| GT200300292A (es) | Derivados de pirimidina para el tratamiento de crecimiento celular anormal | |
| CR10125A (es) | Compuestos de azaindol inhibidores de aurora quinasas | |
| GT200700039A (es) | Derivados de triazolopirazina | |
| CU20110052A7 (es) | Compuestos orgánicos | |
| CY1113485T1 (el) | Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων | |
| CY1118650T1 (el) | Παραγωγα βενζιμιδαζολιου | |
| EA201390015A1 (ru) | Композиции и способы ингибирования пути jak | |
| CY1123919T1 (el) | 1η-βενζιμιδαζολο-4-καρβοξαμιδια υποκατεστημενα με τεταρτοταγη ανθρακα στην 2-θεση ειναι ισχυροι αναστολεις parp | |
| CY1114091T1 (el) | ΠΑΡΑΓΟΝΤΕΣ ΓΙΑ ΠΡΟΛΗΨΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΔΙΑΤΑΡΑΧΩΝ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΟΥΝ ΔΙΑΦΟΡΟΠΟΙΗΣΗ ΤΩΝ ΥΠΟΔΟΧΕΩΝ RyR | |
| ECSP088536A (es) | DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR | |
| BRPI0713555A2 (pt) | ciclopenta [d] pirimidinas como inibidores de akt protéina cinase | |
| BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
| DE602006001515D1 (de) | Chemische verbindungen | |
| MY176944A (en) | Substituted pyrimidines for the treatment of diseases such as cancer | |
| CO6710897A2 (es) | Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer | |
| EA201000946A1 (ru) | Бициклические производные для применения при лечении состояний, связанных с андрогенным рецептором | |
| ECSP078060A (es) | 2,4-diamino-pirimidinas como inhibidores de aurora | |
| EA201291246A1 (ru) | Конденсированные бициклические ингибиторы киназы | |
| MX2008013196A (es) | 5-amido-2-carboxiamida-indoles. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |